Anti-CALLA [SS2/36]
Invented by Dr Jacqueline Cordell from University of Oxford
Invented at University of Oxford
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 151348 |
| Applications | FACS IHC WB |
| Antigen/Gene or Protein Targets | Common Acute Lymphocytic Leukaemia Antigen (CALLA, CD10) |
| Reactivity | Human |
| Relevance | CALLA is expressed on B- and T- cell precursors, bone marrow stromal cells, lymphoblastic, Burkitt’s, and follicular germinal center lymphomas, and on cells from patients with chronic myelocytic leukemia (CML). CALLA is a cell surface enzyme that inactivates a variety of peptides. SS2/36 is a marker for Acute Lymphocytic Luekaemia (ALL). CALLA is widely used for identification of "common" type Acute Lymphocytic Leukaemia (ALL). |
| Host | Mouse |
| Immunogen | Common acute lymphoblastic leukaemia cells |
| Subclass | IgG1 |
| Myeloma Used | P3/NS1/1-Ag4.1 |
| Recommended Growing Conditions | RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT |
| Notes | Ultroser G can be used at 1% if the cells are not growing well. |
| Research Area | Cancer, Cell Type or Organelle Marker, Immunology, Stem Cell Biology |
References: 1 entry
Majdic O, Sugita K, Stockinger H, Skrobal A, Knapp W (1987) Comparative evaluation of CD10 antibodies. In McMichael AJ, et al (eds) Leucocyte Typing III, Oxford University Press, Oxford, New York and Tokyo, p 488-9.
Add a reference
References: 1 entry
Majdic O, Sugita K, Stockinger H, Skrobal A, Knapp W (1987) Comparative evaluation of CD10 antibodies. In McMichael AJ, et al (eds) Leucocyte Typing III, Oxford University Press, Oxford, New York and Tokyo, p 488-9.
Add a reference
